ICCC

Business Context and Reporting Period

Company: IMMUCELL CORP (IMMUCELL CORPORATION)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: A biotechnology company focused on developing animal health products for dairy and beef producers. Key commercialized products include the Kamar Heatmount Detector and First Defense (a calf scours preventive). The company is also conducting Phase II clinical trials for DiffGAM, a human therapeutic for C. difficile infections, and markets Crypto-Scan for detecting pathogens in drinking water.

Key Financial Metrics (Year Ended Dec 31, 1998)

Margins: Product costs were 48% of product sales in 1998 (up from 46% in 1997). R&D expenses represented 23% of total revenues.

Material Changes vs. Prior Period

• Profitability: The company reported a net loss of $102,518 in 1998, a reversal from a net profit of $263,852 in 1997. This was primarily driven by a $122,558 equity loss from its joint venture (AgriCell) and increased general and administrative expenses due to severance costs for the former President.
• Revenue Composition: Total revenues decreased slightly by 2% ($75,000). While product sales increased by 5% ($217,000), "Other revenues" (licensing and grants) dropped significantly from $574,000 in 1997 to $282,000 in 1998. The 1997 figure included a one-time $250,000 technology licensing payment which did not recur in 1998.
• Liquidity: Cash and cash equivalents increased by approximately $518,000 to $1.54 million, supported by operating cash flow of $640,000.
• Debt Structure: In May 1998, the company refinanced its bank debt, replacing multiple notes with a single $480,000 mortgage loan at a fixed rate of 8.62%.

Guidance, Outlook, and Risks

• Strategic Shift: Management intends to reduce internally funded R&D as a percentage of sales to achieve net operating profit. Future R&D will be pursued through external financing, licensing, and government grants.
• Product Pipeline:
  • DiffGAM: Phase II clinical trials for C. difficile treatment are expected to complete in late 1999. The company seeks a corporate partner to fund Phase III trials.
  • TravelGAM: Development discontinued in 1998 following inconclusive/negative trial results.
  • Crypto-Scan: Sales remain limited pending regulatory acceptance (EPA/UK) of the company's concentration and separation technology.
  • Lactoferrin (AgriCell JV): Sales negatively impacted by the Asian financial crisis; the JV recorded a significant loss in 1998.
• Risks:
  • Regulatory: Significant sales of Crypto-Scan and DiffGAM depend on EPA and FDA approvals, respectively.
  • Market: Foreign sales (25% of total) are exposed to currency fluctuations; a strong U.S. dollar negatively impacted Pacific Rim sales in 1998.
  • Capital: Continued profitability depends on the successful marketing of existing animal health products and the ability to secure partners for human health product development.
• Year 2000 Issue: The company estimates costs to address Y2K compliance will not exceed $23,000, with completion expected in Q1 1999.

Investor Verification Checklist

• Joint Venture Losses: Verify the sustainability of the AgriCell joint venture given the $123,000 loss and the impact of the Asian financial crisis on lactoferrin sales.
• Revenue Recurrence: Confirm that the 1997 revenue boost from the $250,000 licensing fee was a one-time event and assess the timeline for future licensing income (e.g., Murray Goulburn royalties expected in 1999).
• Regulatory Milestones: Monitor the status of EPA validation for Crypto-Scan and the completion of DiffGAM Phase II trials in late 1999.
• Debt Covenants: Review the terms of the new $480,000 mortgage loan and ensure compliance with payment schedules to maintain Nasdaq listing requirements (stockholders' equity must remain above $2 million).
• Management Stability: Note the resignation of the former President/CEO in December 1998 and the subsequent reorganization of the executive team.